The story of the erectile dysfunction drug presents a challenging picture for investors. While the initial introduction generated substantial gains, the expiration of its patent opened the avenue to generic competitors, dramatically diminishing revenue. This creates a particular challenge for firms relying on comparable blockbuster offerings, sugge

The history of Viagra, and its creator copyright, presents a challenging case study for investors. At first a blockbuster drug, generating billions in revenue , its exclusivity period created a deluge of generic competition , significantly eroding its position . While certain businesses may attempt to capitalize on similar conditions , the existing